Pembrolizumab in combination with pemetrexed has shown clear efficacy for non-squamous NSCLC, while for patients with squamous NSCLC, pembrolizumab combined with carboplatin and nab-paclitaxel has shown favorable overall survival outcomes in the PD-L1 < 1% subgroup, based on the exploratory analysis of the KEYNOTE-407 trial. Here, CD274 is linked to non-small cell lung carcinoma.